docetaxel anhydrous has been researched along with st 1481 in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (st 1481) | Trials (st 1481) | Recent Studies (post-2010) (st 1481) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 49 | 5 | 15 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W | 1 |
1 other study(ies) available for docetaxel anhydrous and st 1481
| Article | Year |
|---|---|
Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids | 2010 |